These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 31511327)

  • 1. A modular PROTAC design for target destruction using a degradation signal based on a single amino acid.
    Shanmugasundaram K; Shao P; Chen H; Campos B; McHardy SF; Luo T; Rao H
    J Biol Chem; 2019 Oct; 294(41):15172-15175. PubMed ID: 31511327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML).
    Zhang J; Ma C; Yu Y; Liu C; Fang L; Rao H
    J Biol Chem; 2023 Aug; 299(8):104994. PubMed ID: 37392851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalytic in vivo protein knockdown by small-molecule PROTACs.
    Bondeson DP; Mares A; Smith IE; Ko E; Campos S; Miah AH; Mulholland KE; Routly N; Buckley DL; Gustafson JL; Zinn N; Grandi P; Shimamura S; Bergamini G; Faelth-Savitski M; Bantscheff M; Cox C; Gordon DA; Willard RR; Flanagan JJ; Casillas LN; Votta BJ; den Besten W; Famm K; Kruidenier L; Carter PS; Harling JD; Churcher I; Crews CM
    Nat Chem Biol; 2015 Aug; 11(8):611-7. PubMed ID: 26075522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
    Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
    Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
    Ocaña A; Pandiella A
    J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of substrate degrons by E3 ubiquitin ligases and modulation by small-molecule mimicry strategies.
    Lucas X; Ciulli A
    Curr Opin Struct Biol; 2017 Jun; 44():101-110. PubMed ID: 28130986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
    Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
    Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assays and technologies for developing proteolysis targeting chimera degraders.
    Liu X; Zhang X; Lv D; Yuan Y; Zheng G; Zhou D
    Future Med Chem; 2020 Jun; 12(12):1155-1179. PubMed ID: 32431173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC).
    Zhang J; Chen X; Chen C; Li F; Song X; Liu C; Liao K; Su MY; Tan CSH; Fang L; Rao H
    J Med Chem; 2024 Aug; 67(16):13666-13680. PubMed ID: 39114932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.